



Hypo-glycosylated human follicle-stimulating hormone (hFSH^{21/18}) is much more active *in vitro* than fully-glycosylated hFSH (hFSH²⁴)[☆]



George R. Bousfield^{a,*}, Vladimir Y. Butnev^a, Viktor Y. Butnev^a, Yasuaki Hiromasa^b, David J. Harvey^c, Jeffrey V. May^a

^a Department of Biological Sciences, Wichita State University, Wichita, KS 67260-0026, USA

^b Biotechnology Core Facility, Kansas State University, Manhattan, KS 66506, USA

^c Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK

ARTICLE INFO

Article history:

Received 1 November 2013

Accepted 11 November 2013

Available online 1 December 2013

Keywords:

FSH isoforms
Oligosaccharide
FSHR

ABSTRACT

Hypo-glycosylated hFSH^{21/18} (possesses FSH β ²¹ and FSH β ¹⁸ bands) was isolated from hLH preparations by immunoaffinity chromatography followed by gel filtration. Fully-glycosylated hFSH²⁴ was prepared by combining the fully-glycosylated FSH β ²⁴ variant with hCG α and isolating the heterodimer. The hFSH^{21/18} glycoform preparation was significantly smaller than the hFSH²⁴ preparation and possessed 60% oligomannose glycans, which is unusual for hFSH. Hypo-glycosylated hFSH^{21/18} was 9- to 26-fold more active than fully-glycosylated hFSH²⁴ in FSH radioligand assays. Significantly greater binding of ¹²⁵I-hFSH^{21/18} tracer than hFSH²⁴ tracer was observed in all competitive binding assays. In addition, higher binding of hFSH^{21/18} was noted in association and saturation binding assays, in which twice as much hFSH^{21/18} was bound as hFSH²⁴. This suggests that more ligand binding sites are available to hFSH^{21/18} in FSHR than to hFSH²⁴. Hypo-glycosylated hFSH^{21/18} also bound rat FSHRs more rapidly, exhibiting almost no lag in binding, whereas hFSH²⁴ specific binding proceeded very slowly for almost the first hour of incubation.

© 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Carbohydrate heterogeneity results in FSH preparations composed of populations of acidic isoforms (Ulloa-Aguirre and Chapel, 1982; Ulloa-Aguirre et al., 1992a, 1992b; Wide, 1985, 1987). The ratios of these isoforms have been shown to vary under physiological conditions, with the less acidic more abundant in young women and at mid-menstrual cycle, while more acidic isoforms are more abundant in older women and in men (Wide, 1982, 1985; Wide and Bakos, 1993; Zambrano et al., 1995).

Partial N-glycosylation of hFSH β produces two hFSH glycoforms, the classical fully-glycosylated hFSH, which possesses all four N-glycans, and a hypo-glycosylated hFSH, which lacks either one or both β subunit N-glycans (Walton et al., 2001). These glycoforms are most readily evaluated by FSH β Western blotting, which reveals two bands, a 24,000 M_r band, that represents the fully-glycosylated form of the subunit (FSH β ²⁴), and a 21,000 M_r band, that represents a hypo-glycosylated subunit (FSH β ²¹). In principle, hFSH²¹ should represent a less acidic hFSH isoform. Indeed, we

have reported that above pI 5.4 only hFSH²¹ was found in chromatofocusing fractions (Walton et al., 2001). However, hFSH²¹ was also found in the less than pI 4.0 fractions and in all others in between, along with hFSH²⁴ (Bousfield et al., 2008; Walton et al., 2001).

As the activities of hFSH isoforms possessing more 21,000 M_r than 24,000 M_r FSH β were greater than those possessing more 24,000 M_r FSH β , we proposed the hypothesis that hypo-glycosylation of hFSH β increased FSH biological activity (Walton et al., 2001). Analysis of hFSH derived from individual human pituitaries revealed an age-related decreased abundance of hFSH β ²¹ indicating the loss of a potentially more active FSH variant. Western blots of virtually all pituitary and urinary hFSH preparations exhibit both hFSH β subunit variants, regardless of purity (Bousfield et al., 2007; Walton et al., 2001). Exceptions included less acidic FSH isoform fractions that possessed only the 21,000 M_r hFSH β variant mentioned above.

In chromatofocusing experiments, the least acidic hFSH isoform fractions consisted of hFSH²¹, but were heavily contaminated with hLH (Walton et al., 2001). We speculated that the 1–2% FSH activity associated with purified pituitary hLH preparations might consist of the hypo-glycosylated hFSH²¹ glycoform, and captured it with an FSH-specific antibody column. Since reverse-phase HPLC is known to produce the 24,000 M_r hFSH β variant in high purity (Walton et al., 2001), we isolated hFSH β ²⁴ and combined it with

[☆] This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Corresponding author. Tel.: +1 316 978 6088; fax: +1 316 978 3772.

E-mail address: george.bousfield@wichita.edu (G.R. Bousfield).

hCG α to produce a semi-synthetic, fully-glycosylated hFSH preparation that would enable us to compare the biological activities of both glycoforms.

2. Materials and methods

2.1. Hormone preparations

Three purified hLH preparations were obtained from Anne Har-tree following her retirement from Cambridge University (Walton et al., 2001). An additional hLH preparation was obtained from Dr. A.F. Parlow and the National Hormone and Pituitary Program (Ward et al., 1986), along with the hFSH reference preparation, AFP7298A (8560 IU/mg). Recombinant hFSH was purified from a stable, transformed GH₃ cell line, which was the generous gift of Dr. Irving Boime, Washington University, St. Louis, MO. Details of its isolation and characterization will be described in a separate publication. Mutant recombinant hFSH β T26A, expressed in insect cells, was provided by Dr. James A. Dias, Wadsworth Center, Albany, NY (Fox et al., 2001). Purification of hFSH glycoforms is described in the supplement. Equine FSH was isolated from horse pituitaries in our laboratory, following our usual procedures (Bousfield and Ward, 1984). The hCG α preparation was purified as previously reported (Bousfield et al., 1985). HiTrap-NHS columns and Superdex 75 gel filtration columns were obtained from GE Healthcare, Piscataway, NJ.

2.2. Antibodies

A monoclonal antibody 46.3H6.B7, which recognized hFSH and hFSH β , was also provided by Dr. Dias (Bousfield et al., 2007). This antibody was coupled to 1-ml HiTrap-NHS columns following the manufacturer's instructions. The anti-hFSH β monoclonal antibody RFSH20 (recognizes both FSH β and FSH), and anti- α subunit antibody HT13 (recognizes all human α -subunits and glycoprotein hormones), were provided by Dr. Jean-Michel Bidart, Institut de Cancérologie Gustave-Roussy, Paris, France (Walton et al., 2001).

2.3. Glycoform nomenclature

The hFSH glycoforms are differentiated by the relative molecular weights of the FSH β subunit Western blot bands, as indicated by a trailing superscript. Thus, pituitary and urinary hFSH preparations possessing both 21,000 and 24,000 M_r hFSH β variants are designated as hFSH^{24/21}, where the first number indicates the more abundant form. FSH glycoform preparations are designated as either fully-glycosylated hFSH²⁴ (formerly tetra-glycosylated hFSH) and hypo-glycosylated hFSH²¹ (formerly di-glycosylated hFSH), or hFSH^{21/18}. The latter is the variant characterized in the present study.

2.4. FSH glycoform characterization

Western blotting was carried out as described previously (Bousfield et al., 2007). Primary antibodies typically employed were anti-hFSH β monoclonal antibody, RFSH20, anti- α subunit monoclonal antibody, HT13. Oligosaccharides released from hFSH samples by PNGaseF digestion were analyzed by nano-electrospray mass spectrometry (Harvey et al., 2008). FSH iodination and radioligand assay, association and saturation binding assays were performed as described previously (Bousfield and Ward, 1984; Liu et al., 1974, 1984). FSH and FSH subunit carbohydrate analyses were carried out as reported earlier (Bousfield et al., 2000) except that a Dionex ICS-5000 carbohydrate analyzer was employed. Detailed methods can be found in the supplement.

2.5. Edman degradation

Protein sequencing was carried out with an Applied Biosystems (Foster City, CA), Procise, model 494, automated sequencer, following the manufacturer's directions. Automated Edman degradation was carried out on 2 μ g samples applied to Biobrene-coated glass fiber disks that were precycled in the sequencer prior to sample application. A typical experiment consisted of 10 Edman degradation cycles.




Fig. 1. Hypo-glycosylated hFSH isolation from hLH preparations. FSH bound to anti-hFSH β immunoaffinity columns was applied to a 10 \times 300 mm Superdex 75 column and the chromatogram developed as described under Methods. (A) FSH β and FSH α Western blots of reduced samples from the chromatogram in panel C. Anti-FSH β : Lane 1, 1 μ g hFSH (AFP7298A); lane 2, 1 μ g fraction A; lane 3, 1 μ g fraction B; lane 4, 1 μ g fraction C. Anti- α : Lane 5, 1 μ g hFSH (AFP7298); lane 2, 1 μ g fraction A; lane 3, 1 μ g fraction B; lane 4, 1 μ g fraction C. (B) FSH β Western blot of non-reduced samples from the chromatogram in panel C. Lane 1, 1 μ g hFSH (AFP7298A); lane 2, 1 μ g fraction A; lane 3, 1 μ g fraction B; lane 4, 1 μ g fraction C. (C) First round of hFSH isolation. (D) Second round of hFSH isolation. (E) Third round of hFSH isolation. The open bars show portions of each chromatogram containing aggregated hFSH (A) hFSH heterodimer (B), and subunits (C).

3. Results

3.1. FSH glycoform isolation from hLH preparations

FSH was extracted from 100 mg batches of purified hLH three times using 46.3H6.B7 antibody columns. The average total hypo-glycosylated hFSH^{21/18} recovery, based on extracting ten hLH batches three times each, was $44.2 \pm 4.9 \mu\text{g}$ (mean \pm standard deviation) per batch. FSH immunoactivity emerged from a $10 \times 300 \text{ mm}$ Superdex 75 column in three peaks (Fig. 1C–E). The first of these, with retention times of 24.3–24.5 min., consisted of aggregated FSH. Hormone aggregation was confirmed by Western blotting following electrophoresis of reduced samples probed with anti- α monoclonal antibody, HT13 (Fig. 1A, lane 6), and non-reduced hFSH isoform samples probed with anti-hFSH β monoclonal antibody RFSH20 (Fig. 1B, lane 2). Both blots showed the presence of high MW immunoreactive bands indicating aggregation. The hFSH β immunoactivity in the aggregated FSH fraction A was below the limits of detection in the reduced hFSH Western blot (Fig. 1A, lane 2). The second Superdex 75 peak, fraction B retention times 28.2–28.4 min.), possessed the hFSH heterodimer fraction. Based on peak areas, hFSH recoveries from 30 Superdex 75 chromatograms ranged from 6.1 to 27.2 μg , and the average recovery was $13.5 \pm 6.3 \mu\text{g}$ per chromatogram. Western blot analysis revealed the presence of a second hFSH β band at M_r 18,000, as well as the anticipated, 21,000 M_r band (Fig. 1A, lane 3). Because there was more of the latter, we designate this hFSH variant as hFSH^{21/18}. Fraction C, derived from the third Superdex 75 peak (retention times 31.0–31.2 min.), possessed the subunit fraction. Western blot analysis detected both α and FSH β subunit immunoactivities, although most of the latter migrated as a 10,000 M_r band, suggesting proteolytic nicking (Fig. 1A, lanes 4 and 8).




Fig. 2. Hypo- and fully-glycosylated hFSH isolation. (A) Immunopurified hFSH fractionated by Superdex 75 chromatography and fractions analyzed by Western blotting. Fractions indicated by bars and numbers. Insets 1 and 2. Western blot analysis of 1 μg samples of reduced Superdex 75 fractions with FSH β - and FSH α -specific antibodies RFSH20 and HT13, respectively. Lane 1, hFSH AFP7298A; lane 2, fraction A; lane 3, fraction B; lane 4, fraction C; lane 5, fraction D. The arrows show the positions of the hFSH β 21,000 and 24,000 M_r bands, as indicated. (B) The 24,000 M_r hFSH β was combined with hCG α and incubated for 72 h at 37 °C. The mixture was reduced to $<200 \mu\text{l}$ and applied to a Superdex 75 column as described under Methods. Insets 3 and 4, FSH β and FSH α Western blot analysis of reduced Superdex 75 fractions, respectively. Lane 1, hFSH²⁴; lane 2, pituitary hFSH (AFP7298A).

The hFSH^{21/18} heterodimer fraction isolated from a second hLH preparation was relatively more abundant than the aggregated FSH and subunit fractions (Fig. 2A). Western blotting of reduced samples from fraction A in this chromatogram, using both anti-hFSH β (RFSH20) and anti-human α -subunit (HT13) antibodies, revealed high MW immunoreactive bands, consistent with aggregation, (Fig. 2A, lane 2 in insets 1 and 2). Both 18,000 and 21,000 M_r bands were observed in the FSH β Western blot for the heterodimer fraction B (Fig. 2A, inset 1, lane 3). As Edman degradation revealed only FSH α and β N-terminal sequences (Supplement Table 1), the 18,000 M_r band appeared to represent another variant of intact hFSH β rather than a subunit fragment. In fraction C, the subunit Western blot, only hFSH β immunoactivity was detectable (Fig. 2A, insets 1 & 2, lane 5). However, Edman degradation revealed the presence of both α and FSH β subunit amino acid sequences (Supplement Table 2), consistent with the presence of both subunits in Western blot analysis of other hypo-glycosylated hFSH^{21/18} preparations (Fig. 1A).

3.2. Preparation of fully-glycosylated hFSH²⁴

Reassociation of 874 μg HPLC-purified, 24,000 M_r hFSH β (Walton et al., 2001) with 2640 μg hCG α , followed by gel filtration over Superdex 75, produced 834 μg fully-glycosylated hFSH in the heterodimer fraction (Fig. 2B, bar). The heterodimer fraction possessed both hFSH β and hCG α subunit immunoactivities according to Western blots with RFSH20 and HT13 monoclonal antibodies, respectively (Fig. 2B, insets 3 and 4, lane 1). A $<21,000 M_r$ band was detected in the hFSH β Western blot that represented $<2\%$ of the immunoactivity (the 24,000 M_r band signal was saturated), much less than the 20% typically encountered in pituitary hFSH preparations (Fig. 2B, inset 3, lane 2).

3.3. FSH glycoform receptor-binding competition assays

The availability of hFSH glycoform preparations permitted us to test the hypothesis, based on previous studies, that the presence of the carbohydrate-deficient hFSH β ²¹ provides hFSH with greater FSH receptor-binding activity than hFSH variants possessing largely or exclusively the fully-glycosylated 24,000 M_r FSH β ²⁴ subunit (Walton et al., 2001). Both hFSH glycoform preparations were compared with two other FSH preparations: a highly active, hypo-glycosylated eFSH preparation, purified in this laboratory (Bousfield and Ward, 1984), that largely lacks βAsn^7 glycans (Dalpathado et al., 2006), and a highly purified 70/30 mixture of hFSH²⁴ and hFSH²¹ glycoforms, obtained from the National Hormone and Pituitary Program (AFP7298A). For reasons of clarity, we will limit labeling of β subunit relative molecular weight to hFSH preparations. All seven eFSH preparations purified in our laboratory were 90% hypo-glycosylated, possessing the 18,000 M_r eFSH β band, while fully-glycosylated eFSH β had a relative molecular weight of 21,000, reflecting a combination of largely biantennary instead of tri- and tetra-antennary glycans attached to eFSH, with a significant percentage of these terminated with sulfate rather than sialic acid (Bousfield et al., 2004; Dalpathado et al., 2006).

When rat testis FSH receptors were employed (Fig. 3A and Table 1) and ¹²⁵I-hFSH²⁴ was used as tracer, cold hypo-glycosylated hFSH^{21/18} was a highly significant, 9-fold more active than cold fully-glycosylated hFSH²⁴ ($p < 0.0001$). Despite its high activity relative to highly purified pituitary hFSH^{24/21}, the hypo-glycosylated hFSH^{21/18} preparation was significantly less active than the eFSH preparation ($p = 0.023$). The activity of fully-glycosylated hFSH²⁴ was not significantly different from pituitary hFSH^{24/21} ($p = 0.132$).

When ¹²⁵I-hFSH^{21/18} was employed as tracer with rat testis homogenate, a highly significant ($p < 0.0001$) 26-fold greater activity for hypo-glycosylated hFSH^{21/18} was observed as compared




Fig. 3. FSH receptor-binding assays of fully- and hypo-glycosylated hFSH preparations. (A) ^{125}I -fully-glycosylated hFSH 24 tracer and rat testis homogenate. (B) ^{125}I -hypo-glycosylated hFSH $^{21/18}$ tracer with rat testis homogenate. (C) ^{125}I -hypo-glycosylated hFSH $^{21/18}$ tracer with CHO cells expressing hFSHR. Receptor-binding assays carried out as described under Methods. Quantitative results are shown in Table 1.

with fully-glycosylated hFSH 24 (Fig. 3B and Table 1). The activities of fully-glycosylated hFSH 24 and pituitary hFSH $^{24/21}$ were not significantly different ($p = 0.771$), while those of hypo-glycosylated hFSH $^{21/18}$ and eFSH were significantly different ($p = 0.0028$). A major difference between assays employing different hFSH glycoform tracers was in the magnitude of the specifically bound cpm, as the same amount of testicular homogenate, although prepared separately for each experiment, bound 14,733 cpm ^{125}I -hFSH $^{21/18}$, which was over 5 times as much as the 2621 cpm representing the specifically bound ^{125}I -hFSH 24 tracer. As will be shown below, the same phenomenon was observed when both tracers were simultaneously incubated with the same receptor preparation.

Table 1
FSH receptor binding assay comparison of hFSH glycoform preparations.

Receptor prep.	Rat testis homogenate		Rat testis homogenate		CHO ^{hFSHR} cells	
	^{125}I -hFSH $^{21/18}$		^{125}I -hFSH 24		^{125}I -hFSH $^{21/18}$	
Tracer	ID $_{50}$ (ng)	Relative potency (IU/mg)	ID $_{50}$ (ng)	Relative potency (IU/mg)	ID $_{50}$ (ng)	Relative potency (IU/mg)
Pit-hFSH $^{24/21a}$	7.85	8560	63.7	8560	554.0	8560
hFSH 24	5.83	11,526	69.6	7834	253.1	18,737
hFSH $^{21/18}$	0.646	104,019	2.67	204,221	17.6	269,445
eFSH	0.468	143,581	1.43	381,309	10.4	455,985
hFSH $^{21/18}$:hFSH 24	9		26		14	

^a Pituitary hFSH preparation AFP7298A, 8560 IU/mg.

We also compared the four FSH preparations in a competitive human FSHR binding assay using intact CHO cells expressing the hFSHR and the better of the two tracers, ^{125}I -hFSH $^{21/18}$. Based on ID $_{50}$ values, hypo-glycosylated hFSH $^{21/18}$ was 14-fold more active ($p < 0.0001$) than fully-glycosylated hFSH 24 (Fig. 3C and Table 1). Interestingly, the curves for the human glycoform preparations were not parallel, despite the use of homologous tracer and receptor preparation. The displacement curve for hypo-glycosylated hFSH $^{21/18}$ appeared to be more parallel to the eFSH curve, which was the most active preparation in this assay, especially at higher concentrations. Based on ID $_{50}$ values eFSH was significantly more active than hFSH $^{21/18}$ ($p < 0.0001$). The least active preparations were fully-glycosylated hFSH 24 and pituitary hFSH $^{24/21}$, which did not differ significantly based on ID $_{50}$ comparison ($p = 0.368$).

3.4. FSHR saturation binding studies

When the same rat testis FSH receptor preparation was exposed to increasing concentrations of both ^{125}I -labeled hFSH glycoforms, in the presence or absence of 2000-fold excess cold eFSH, 2-fold greater specific binding was observed for ^{125}I -hFSH $^{21/18}$ than for ^{125}I -hFSH 24 (Fig. 4).

3.5. FSHR association studies

The radioligand assay procedure routinely employed in this laboratory was modified for association studies because samples in the latter studies were removed at 15-min intervals, while separation of bound from free hormone in the former procedure involved a 20-min centrifugation step. In the modified assay, tubes were incubated at 37 °C for the indicated times, then placed in an ice bath until incubation of all the tubes was completed, when all assay tubes were centrifuged together. To prevent continued FSH binding during the ice bath step, 2000-fold excess eFSH was added to each tube and the binding compared with tubes lacking cold hormone. A small, but statistically non-significant difference was noted between the binding curves, indicating that binding did not continue at 4 °C, nor was there significant dissociation from the receptor. In subsequent experiments, tubes removed at different times were stored at 4 °C in the absence of cold hormone and all were centrifuged together following removal of the last tubes from the incubator. Moreover, when receptor binding was measured following 3 h incubation at 4 °C, no significant binding of ^{125}I -hFSH $^{21/18}$ or ^{125}I -hFSH 24 was observed. While ^{125}I -eFSH binding to FSH receptors was observed in this experiment (data not shown), this tracer was not used in any studies reported herein.

In the association study (Fig. 5), the ^{125}I -hFSH 24 tracer exhibited a similar binding pattern as ^{125}I -pituitary hFSH $^{24/21}$. The hypo-glycosylated hFSH $^{21/18}$ binding was greater than either of the other tracers at all time points and this seemed at least partially due to the absence of lag during the first 30–50 min. Both ^{125}I -hFSH tracer preparations possessing fully-glycosylated hFSH exhibited very

limited receptor binding during this interval. Beginning with the 60 min time point, increased binding of both tracers commenced and progressed at the same rate as hypo-glycosylated hFSH^{21/18} binding, reaching a maximum at 3 h. A lower maximum binding of hFSH²⁴ tracer as compared with hypo-glycosylated hFSH^{21/18} was noted. In contrast, ¹²⁵I-hFSH^{21/18} binding began with little or no lag and reached its maximum extent by 3 h.

3.6. Comparison with recombinant insect cell hFSH in Western blots

Nano-electrospray mass spectrometry revealed that 60% of hFSH^{21/18} glycans were oligomannose glycans (Supplement Figs. 2–4 and Supplement Tables 3 and 4), which are rare in pituitary hFSH (Bousfield et al., 2008; Dalpathado et al., 2006; Green and Baenziger, 1988; Renwick et al., 1987), but common in recombinant, insect cell-expressed glycoprotein preparations (Altmann et al., 1999). We compared the pituitary hFSH glycoform subunit electrophoretic mobilities with those of wild type and glycosylation site-mutated, insect cell-expressed recombinant hFSH preparations in subunit-specific Western blots (Fig. 6). The hypo-glycosylated hFSH β immunoactivity migrated as 3 bands at M_r 21,000, 20,000, and 18,000 (Fig. 6A, lane 2). Most of the immunoactivity was associated with the 21,000 and 18,000 M_r bands (hFSH β ²¹ and hFSH β ¹⁸, respectively). The hFSH β ¹⁸ band migrated faster than the 19,000 M_r wild type recombinant insect hFSH β band (compare lanes 2 and 4). It exhibited the same mobility as the 18,000 M_r β T26A-hFSH mutant band (lane 7), as if pituitary hFSH β ¹⁸ also possessed a single, oligomannose N-glycan. The hFSH β ²¹ migrated more slowly than the 19,000 M_r, fully-glycosylated recombinant insect hFSH β subunits (compare lane 2 with lanes 4–6). A sample of bacterially expressed hFSH β was largely aggregated as evidenced by the 167,000 M_r band near the top of the gel and the broad region of immunoreactivity ranging from 26,000 to 48,000 M_r. The fastest migrating form in this preparation appeared as a pair of bands at 15,000 and 16,000 M_r, which was similar to the pattern for PNGaseF-sensitive hFSH β (see Supplement Figs. 7 and 8). Thus, the mobility of even the 15,000 M_r bacterially expressed hFSH β band was slower than expected for a protein with a formula weight of 12,485.

While the α subunit band mobilities varied between hFSH preparations, no separate bands were observed (Fig. 6B). The relative molecular weight of pituitary hFSH α was 23,000 M_r, as it exhibited the slowest migration of the human FSH α -subunit preparations, the hypo-glycosylated hFSH α band was 20,000 M_r, and the slowest component migrated immediately ahead of the fastest element of

the 23,000 M_r pituitary hFSH α band. The hCG α possessed by the fully-glycosylated hFSH²⁴ preparation exhibited a band with intermediate relative molecular weight (21,000 M_r), probably because of the largely hybrid-type Asn⁵² glycans and biantennary Asn⁷⁸ glycans (Weisshaar et al., 1991), as compared with mostly tri- and tetra-antennary hFSH glycans presumably associated with the pituitary hFSH α preparation (Green and Baenziger, 1988; Renwick et al., 1987). Only the wt recombinant insect hFSH and β T26A mutant recombinant insect hFSH preparations possessed both α and FSH β subunit bands indicating the presence of heterodimeric FSH. This was consistent with the observation of heterodimer peaks in the Superdex 75 gel filtration chromatograms for both the wt and β T26A preparations, while the α -subunit mutant chromatograms contained only the subunit peak (data not shown). It is possible the α T80A mutant α subunit was below the limits of detection because, the absence of Asn⁷⁸ glycan affected HT13 antibody binding (Supplement Figs. 7 and 8). In both wt and β T26A recombinant insect hFSH preparations, the α subunit band mobilities were greater than those for any pituitary hFSH preparation α subunit bands, including hypo-glycosylated hFSH^{21/18}. If 21,000 M_r hFSH β indicated the di-glycosylated hFSH preparation reported earlier (Bousfield et al., 2007), most of the glycans released by PNGaseF digestion should have come from the α subunit, yet its mobility was slower than α subunit associated with both heterodimeric insect hFSH preparations.

3.7. Hypo-glycosylated hFSH β subunit characterization

Hypo-glycosylated hFSH α and β subunits were separated from pooled hypo-glycosylated hFSH subunit fractions by 46.3H6.B7 immunopurification followed by Superdex 75 gel filtration of the unbound and bound fractions, respectively (Supplement Fig. 5). The yield of hypo-glycosylated hFSH β appeared to be greater than that of hFSH α , consistent with the absence of detectable α subunit immunoactivity in some subunit fraction Western blots (Fig. 2A, inset). Automated Edman degradation revealed both hFSH β subunit N-terminal and internal amino acid sequences for the hypo-glycosylated hFSH β preparation (Supplement Table 5), which was consistent with the appearance of fragment bands in Western blots of the subunit fraction (Figs. 1 and 2). Only the α subunit N-terminal sequence was observed during Edman degradation of the hFSH α preparation (Supplement Table 6).

Neutral and amino sugar analysis of both α and β subunits revealed the presence of carbohydrate in both subunit preparations (Table 2). Mannose yields were highest for all the monosaccharide residues detected in both subunit hydrolysates, consistent with quantitative MS data that indicated 60% of N-glycans released from hypo-glycosylated hFSH^{21/18} were oligomannose, which possessed 3–9 mannose residues in addition to two GlcNAc residues (Supplement Table 3). Relative mannose abundance data indicated hypo-glycosylated hFSH^{21/18} glycans possessed an average of 4.7 mol mannose/mol glycan. Using this value, we normalized the compositions for both the α and β subunits. The results indicated a lower GlcNAc content in α subunit glycans, suggesting enrichment of oligomannose glycans in this subunit. Indeed, we previously reported oligomannose glycans largely associated with α Asn⁵⁶ (homologous to human α Asn⁵²) in horse LH preparations (Bousfield et al., 2004).

Hypo-glycosylated FSH β subunit glycans possessed the typically higher fucose content as well as a higher GlcNAc content. The latter suggested more complex-type glycans were attached to this subunit than to the FSH α subunit. While the same relative amounts of galactose in both subunits suggested the same extent of branching in complex glycans, if FSH α in the subunit fraction represented free- α , rather than dissociated FSH α , O-glycosylation was possible. Bovine pituitary free α -subunit was reported to be O-glycosylated at Thr⁴³ (Thr³⁹ is the homologous human α -subunit




Fig. 4. Saturation binding of hypo- and fully-glycosylated hFSH preparations to rat testis FSH receptors. The same rat testis homogenate was used to measure specific binding of both glycoforms. Closed circles, saturation binding of ¹²⁵I-hypo-glycosylated hFSH. Closed squares, saturation binding of ¹²⁵I-fully-glycosylated hFSH. Specific binding (Bo – Bn) was determined using 2000-fold excess cold eFSH. Representative data from two experiments.




Fig. 5. Association kinetics for hypo- and fully-glycosylated hFSH binding to rat testis FSH receptors. FSH glycoform tracers, in the presence and absence of 2000-fold cold eFSH, were incubated with rat testis FSH receptors at 37 °C for the indicated times, then placed in an ice water bath. When all the tubes were incubated, they were centrifuged to separate bound from free hormone, the supernatants aspirated and ^{125}I -hFSH glycoform bound to the pellets counted in a gamma counter. Specific binding is plotted against incubation time. Representative data from three experiments.




Fig. 6. Comparison of recombinant insect hFSH subunit electrophoretic mobilities with those of pituitary FSH glycoforms. (A) FSH β -Western blot comparing mobilities of hFSH glycoforms with those of recombinant insect cell hFSH β subunit preparations. The primary antibody was RFSH20. (B) FSH α -Western blot using HT13 primary antibody. The same preparations were compared in both blots. Lane 1, pituitary hFSH (AFP4161B); lane 2, hypo-glycosylated hFSH; lane 3, fully-glycosylated hFSH; lane 4, wt recombinant insect hFSH; lane 5, α T54A mutant recombinant insect hFSH; lane 6, α T80A mutant recombinant insect hFSH; lane 7, β T26A mutant recombinant insect hFSH; lane 8, recombinant bacterial hFSH β . Pre-stained BioRad MW marker positions are indicated by lines.

residue), which is exposed in the free subunit, but not in the intact hormone (Parsons et al., 1983). Alternatively, the presence of complex glycans at one of the hFSH $^{21/18}\alpha$ subunit glycosylation sites

might be responsible for the slower migration during electrophoresis than insect-expressed FSH α subunits, which possessed exclusively oligomannose glycans. Compositions for the latter included GlcNAc, Man, and Fuc, but no Gal (Table 3).

4. Discussion

4.1. Hypo- and fully-glycosylated hFSH preparation

The existence of two major hFSH glycoforms resulting from hFSH β macroheterogeneity was inferred from subunit-specific Western blots, which revealed hFSH β^{24} and FSH β^{21} bands accompanied by a single hFSH α band (Bousfield et al., 2007; Walton et al., 2001). Confirmation of hypo-glycosylated hFSH glycoform existence required isolation of this variant. While evaluating potential sources of di-glycosylated hFSH (now designated hFSH 21), the least acidic chromatofocusing fractions were considered because they possessed only the hFSH β^{21} band in FSH β -specific Western blots (Walton et al., 2001). However, these fractions possessed only a small percentage of the total hFSH recovered. Moreover, significant hLH contamination was present in these fractions, which suggested examining preparations of this hormone (Timossi et al., 2000; Walton et al., 2001).

As 2.4 grams of hLH were available in the laboratory, we proceeded under the working hypothesis that the 1–2% FSH activity associated with most pituitary LH preparations represented hFSH 21 and anticipated recovering as much as 24 mg of this variant. However, the receptor-binding activity measurements grossly overestimated the FSH mass because purified hFSH $^{21/18}$ exhibited as much as 26-fold greater activity in rat FSH receptor-binding assays than the hFSH reference preparation used to quantify FSH (Fig. 3). Thus, the actual mass of hFSH present in hLH was less than 1 mg and only 500 μg of that was recovered, which limited biochemical and biological characterization. As all other hFSH isoform fractions possessed a mixture of both hFSH 24 and hFSH 21 and no purification method was available at that time, fully-glycosylated hFSH 24 was reconstituted from HPLC-purified FSH β^{24} combined with purified hCG α . The latter was employed to avoid FSH β^{21} contamination associated with HPLC-purified FSH α preparations (Walton et al., 2001).

4.2. FSH receptor binding

Before discussing the increased FSHR binding activities associated with hFSH $^{21/18}$, it is important to realize that hypo-glycosylated hFSH preparations have been shown to be active in animal studies conducted by our collaborator, Dr. T.R. Kumar, University of Kansas Medical Center, Kansas City, KS. *In vivo* studies comparing hFSH 24 with hypo-glycosylated hFSH $^{21/18}$ preparations show a similar pattern of rapid onset of stimulation and higher level of ovarian response in *Fshb* null mice to hFSH $^{21/18}$. These unpublished studies firmly establish the physiological significance of the receptor-binding data reported herein (Kumar, T.R., et al., manuscript in preparation).

Table 2

Neutral and amino sugar composition of hypo-glycosylated hFSH $^{21/18}$ subunit preparations.

Subunit prep.	hFSH $^{21/18}\alpha$	hFSH $^{21/18}\beta$
Monosaccharide	mol/4.7 mol Man	
Fucose	0.1	0.5
GalNAc	0.2	0.1
GlcNAc	2.2	3.1
Galactose	0.7	0.7
Mannose	4.7	4.7

Comparison of glycoform ID₅₀ values in FSH receptor-binding assays revealed a 9- to 26-fold higher apparent affinity for hFSH^{21/18} than for hFSH²⁴. The latter was as active as purified pituitary hFSH^{24/21}, indicating full recovery of biological activity in the heterodimer fraction following subunit reassociation. We have subsequently isolated pituitary hFSH²⁴ preparations (unpublished data), which exhibited reduced activity compared with purified pituitary hFSH^{24/21}, suggesting the activity of reconstituted hFSH²⁴ represents the high end of the activity scale for pituitary hFSH²⁴ preparations. The unexpectedly high receptor-binding activity of hFSH^{21/18} represented almost 10-fold greater activity than had been reported for other carbohydrate-deficient hFSH preparations.

Chemically deglycosylated hFSH was reported to be as active as, or up to 3-fold more active than native hFSH in porcine and bovine FSH receptor assays (Calvo et al., 1986). Recombinant hFSH preparations produced mixed results when FSH β glycosylation sites were mutated to prevent glycan addition. In one study, the activity of the recombinant, HEK293 cell-derived mutant hFSH preparation, β Asn7Gln, increased rat testis FSH receptor binding 2.5-fold, but decreased rat granulosa cell bioassay activity to 52% that of wild type recombinant hFSH (Flack et al., 1994). The β Asn24Gln mutant exhibited 87% greater FSH receptor binding activity, but 59% reduced granulosa cell activity. Another laboratory reported no significant difference in FSH receptor binding activity between β Asn7Gln or β Asn24Gln mutant preparations and wild-type, CHO cell-expressed recombinant hFSH using rat testis membrane preparations (Bishop et al., 1994). In the Sertoli cell estradiol production assay, the biologic activity of both mutants was reduced by 31% or 25%, respectively. Mutating FSH β glycosylation sites may affect hormone conformation and possibly heterodimer stability (Flack et al., 1994). The latter could reduce activity, as heterodimeric FSH structure is necessary for high affinity FSHR binding (Fan and Hendrickson, 2005).

Specific binding of ¹²⁵I-hFSH²⁴ tracer in the rat testis homogenate competition assays was 2%, which was much lower than the 8% observed for ¹²⁵I-hFSH^{21/18} tracer. The specific activities for both tracers were very similar, 39 and 42 μ Ci/ μ g, respectively; indicating the difference in bound cpm represented a difference in the amount of FSH glycoform bound to the receptor. In the presence of excess rat testis homogenate, 2-fold more of 2.5 ng ¹²⁵I-hFSH^{21/18} was bound than of the same amount of ¹²⁵I-hFSH²⁴. The difference in the maximum bindable fraction was difficult to rationalize, as iodine most likely modified either Tyr⁸⁸ or Try⁸⁹ in the α subunit C-terminus (Stanton and Hearn, 1987). Neither residue was close to the FSH β N-glycans, and changes in FSH iodination in response to altered FSH β glycosylation should have been attended by altered iodine incorporation, although a different distribution of iodine label was also possible. Saturation binding of both hFSH glycoforms confirmed the 2-fold difference in binding to rat testis FSH receptors (Fig. 4). If the difference in bindable fraction between both tracers was responsible for the twofold greater uptake of 2.5 ng ¹²⁵I-hFSH^{21/18}, then at a concentration of 3000 fmol/ml, ¹²⁵I-hFSH²⁴ should have approached the same level of binding as 1500 fmol/ml ¹²⁵I-hFSH^{21/18}. Instead, the 2-fold dif-

ference was retained, suggesting that FSH β glycosylation influenced the number of FSH binding sites available.

As FSH receptors are now known to exist as at least dimers (Guan et al., 2010; Mazurkiewicz et al., 2006; Urizar et al., 2005), the number of available binding sites may be affected by N-glycans of hFSH bound to one site affecting binding to a second FSH-binding site through an allosteric mechanism. However, both crystal structures of hFSH bound to the FSHR extracellular domain showed hFSH β glycans oriented away from the hormone-receptor interface, where they should have no effect on receptor binding (Fan and Hendrickson, 2005; Jiang et al., 2012). The trimeric arrangement of enzymatically deglycosylated hFSH bound to the full-length extracellular domain led to a proposal that the non-reducing terminus of FSH α Asn⁵² glycan could occupy the binding site filled by the reducing terminal FSH α Asn⁵² glycan of a second hFSH ligand (Jiang et al., 2013). Evidence supporting this structure-based hypothesis came from modeling a biantennary glycan attached to α Asn⁵², which fit the notch between two extracellular domains normally occupied by the same glycan attached to a different FSH molecule, and from comparison of wt- and α Asn⁵² mutated hFSH binding. Threefold more mutant hFSH was bound than wt-hFSH in saturation binding studies (Jiang et al., 2013). The hCG α glycans in the hFSH²⁴ preparation could substitute for the biantennary glycan in the FSHR-ECD model because the complex branch possesses the same structure: Neu5Ac(α 2-3)Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-3), which provides the extended branch used in the modeling exercise. The corresponding branch in largest oligomannose glycan associated with hFSH^{21/18}, GlcNAc₂Man₉, is one residue shorter and the α -glycosidic bonds connecting the Man residues produce a helical rather than extended shape. However, the mobility of hFSH^{21/18} α was more similar to that of hCG α than to recombinant insect hFSH α . Since the hFSH^{21/18} α carbohydrate composition suggests a mixture of complex and oligomannose glycans, which is consistent with its intermediate electrophoretic mobility, it will be important to determine the α Asn⁵² glycan population in hypo-glycosylated hFSH glycoform preparations.

Association studies revealed another interesting difference between hFSH²⁴ and hFSH^{21/18} binding to the FSH receptor. For the first 50 min of incubation at 37 °C, specific binding of hFSH²⁴ tracer proceeded very slowly, whereas hFSH^{21/18} binding commenced with almost no delay. At 60 min the rate of hFSH²⁴ tracer binding increased and proceeded at the same rate as for hFSH^{21/18} (Fig. 5). Once again, the maximum binding of ¹²⁵I-hFSH^{21/18} was 80% greater than that of ¹²⁵I-hFSH²⁴. Chemically deglycosylated oLH was reported to bind rat LH receptors faster than intact oLH (Liu et al., 1984), which could have either indicated a difference in how these related receptors interacted with their ligands or reflected removal of the inhibitory influence of oLH α Asn⁵⁶ glycan (homologous to human α Asn⁵²) on LH receptor binding (Butnev, Gotschall, Butnev et al., 1998).

When trying to rationalize the presence of hFSH²¹ in the most acidic hFSH isoform fractions, despite the absence of one or more N-glycans, as well as the lack of increased abundance of more negatively charged glycans in this fraction, we suggested dimerization of hFSH²¹ and hFSH²⁴ with either glycoform. Dimerization com-

Table 3

Carbohydrate compositions for FSH β subunit samples derived from hypo-glycosylated pituitary, GH₃⁻, and insect-cell hFSH preparations.

Preparation	hFSH ^{21/18} β ^a	GH ₃ -hFSH β	β T26AFSH β	α T54AFSH β	α T80AFSH β
Monosaccharide residue	mol/3 mol Man				
Fucose	0.3	1.9	2.6	1.9	1.0
Galactosamine	–	0.2	0.1	0.1	0.1
Glucosamine	2.0	6.0	3.4	3.5	3.7
Galactose	0.4	1.9	0.2	–	–
Mannose	3	3	3	3	3

^a Data from Table 2 normalized to 3 mannose residues to facilitate comparison.

bined two glycan populations and glycoforms with different overall net charges ended up in the same isoform fraction because of the average overall charge for two molecules rather than one (Bousfield et al., 2008). Supporting evidence consisted of a small increase in molecular size indicated by Superdex 75 gel filtration (Bousfield et al., 2008). In the present study we demonstrated that gel filtration over two Superdex 75 columns connected in series separated hFSH²⁴ from hFSH^{21/18} (Supplement Fig. 1). With the previous model of all-or-none glycosylation of hFSH β (Walton et al., 2001), the rationale for the greater apparent molecular size for hFSH²⁴ was the presence of hFSH β ²⁴ N-glycans that roughly doubled the narrow diameter of the hormone as compared with hFSH²¹ lacking both hFSH β glycans (Bousfield et al., 2008). Since evidence in the present study indicated that at least some of hFSH β ²¹ or hFSH β ¹⁸ bands represented partially glycosylated hFSH β , an alternative explanation for the higher molecular weight of hFSH²⁴ was that it existed as dimers of heterodimers. The orientation of hFSH heterodimers in the crystal structure of hFSH (Fox et al., 2001) was such that the receptor-binding surfaces interacted with each other, preventing receptor binding. If these FSH heterodimeric dimers existed in solution, then they would have to separate into monomers of FSH before binding the receptor. Dissociation might require 50–60-min, accounting for the lag in hFSH²⁴ binding.

4.3. Hypo-glycosylated hFSH glycosylation

The higher apparent affinity, more rapid binding, and greater number of FSH receptor binding sites associated with hFSH^{21/18} indicated altered glycosylation exhibited a significant effect on hFSH glycoform biological activity. Glycosylation of the hFSH^{21/18} glycoform preparation isolated from hLH differed from that of pituitary hFSH^{24/21} used as a biological and biochemical reference preparation in our studies to a greater extent than was anticipated. While the hFSH^{21/18} lacked the hFSH β ²⁴ band and possessed the hFSH β ²¹ band in FSH β -specific Western blots, it also possessed an hFSH β ¹⁸ band that comprised 40% of the FSH β immunoactivity. The hFSH β ¹⁸ band did not represent a fragment because automated Edman degradation detected only the hFSH β amino terminal residues. Moreover, nano-ESI mass spectrometry revealed a glycan population dominated by oligomannose oligosaccharides, including several intermediates in the N-glycan processing pathway. Taken together with low abundance of this glycoform, the presence of oligomannose glycans suggested hFSH^{21/18} might have represented a biosynthetic intermediate of hFSH that is physiologically irrelevant. However, other evidence indicated this was unlikely, as complex N-glycans comprised over 30% of the hFSH^{21/18} oligosaccharide population and carbohydrate composition data provided evidence that both complex and oligomannose glycans were present in the FSH^{21/18} α subunit preparation. Moreover, hypo-glycosylated hFSH preparations are active *in vivo*.

Western blots revealed FSH^{21/18} α as a single band that exhibited an intermediate mobility between the complex glycan-dominated FSH α and hCG α subunit bands and the exclusively oligomannose glycan-decorated insect hFSH α band. Carbohydrate composition analysis of the FSH α fraction indicated a mixture of oligomannose and complex glycans due to the high ratio of Man and the presence of both Gal and GalNAc residues typical of complex N-glycan branches. The presence of two hFSH β subunit bands in hFSH^{21/18} Western blots was also consistent with both types of glycans, but distinct mobilities were observed because only a single glycan was present, while the α subunit possessed two N-glycans and intermediate electrophoretic mobility was consistent with one of each glycan type residing in the same α subunit molecule. The co-migration of the hFSH β ¹⁸ band with the recombinant insect hFSH β band suggested that it might possess a single oligomannose

glycan. This might explain its apparent absence in other hFSH preparations. While it is possible that hFSH β ¹⁸ was below the detection limits of our Western blotting procedure, the glycan population of another hFSH²¹ preparation purified from pituitary hFSH fractions, was very similar to that of purified pituitary hFSH^{24/21} including the almost complete absence of oligomannose glycans (Bousfield and Harvey, unpublished).

4.4. Conclusion

Hypo-glycosylated hFSH represents a naturally occurring glycosylation variant that exhibits different structural and functional properties than the classical fully-glycosylated glycoform. When first discovered, we could only speculate that hypo-glycosylated hFSH action differed, perhaps by providing an episodic signal to the gonads, much like has been demonstrated for LH in peripheral circulation (Padmanabhan et al., 1997; Plant et al., 1978; Reame et al., 1984). The present study shows that hypo-glycosylated hFSH binds the FSH receptor more rapidly and can access more binding sites than fully glycosylated hFSH. In sheep hypothalamo-hypophysial portal blood, episodic release of FSH was demonstrated that could not be detected in peripheral blood, at least in part due to a high background of tonic FSH secretion (Padmanabhan et al., 1997). Episodically released hypo-glycosylated hFSH might contribute to this pattern if it is cleared rapidly, as expected from recombinant hFSH glycosylation mutant clearance studies (Bishop et al., 1995). Rapid clearance involves escape from capillaries, and in the gonads, this can mean rapid FSH delivery to target cells where hypo-glycosylated hFSH can quickly bind and activate FSH receptors. Thus, the apparent loss of hypo-glycosylated FSH as a function of age may contribute to reduced fertility associated with aging. The effects of reduced hFSH²¹ abundance would be manifested around the time of ovulation, when a recent report suggests such hypo-glycosylated hFSH concentrations are elevated in the circulation (Wide and Ericksson, 2013). Loss of this form could adversely affect follicle development (West et al., 2002) and oocyte maturation (Andersen et al., 2001), thereby contributing to infertility.

Acknowledgements

This research was supported by NIH Grants P01 AG-029531, G20 RR-031092, P20 RR-016475, and matching funds from Wichita State University.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.mce.2013.11.008>.

References

- Altmann, F., Staudacher, E., Wilson, I.B., Marz, L., 1999. Insect cells as hosts for the expression of recombinant glycoproteins. *Glycoconj. J.* 16, 1091–1123.
- Andersen, C.Y., Leonardsen, L., Ulloa-Aquirre, A., Barrios-de-Tomasi, J., Kristensen, K.S., Byskov, A.G., 2001. Effect of different FSH isoforms on cyclic-AMP production by mouse cumulus-oocyte complexes: a time course study. *Mol. Hum. Reprod.* 7, 129–135.
- Bishop, L.A., Robertson, D.M., Cahir, N., Schofield, P.R., 1994. Specific roles for the asparagine-linked carbohydrate residues of recombinant human follicle stimulating hormone in receptor binding and signal transduction. *J. Mol. Endocrinol.* 8, 722–731.
- Bishop, L.A., Nguyen, T.V., Schofield, P.R., 1995. Both of the b-subunit carbohydrate residues of follicle-stimulating hormone determine the metabolic clearance rate and *in vivo* potency. *Endocrinology* 136, 2635–2640.
- Bousfield, G.R., Ward, D.N., 1984. Purification of lutropin and follitropin in high yield from horse pituitary glands. *J. Biol. Chem.* 259, 1911–1921.
- Bousfield, G.R., Liu, W.-K., Ward, D.N., 1985. Hybrids from equine LH: alpha enhances, beta diminishes activity. *Mol. Cell. Endocrinol.* 40, 69–77.

- Bousfield, G.R., Baker, V.L., Gotschall, R.R., Butnev, V.Y., Butnev, V.Y., 2000. Carbohydrate analysis of glycoprotein hormones. *Methods* 21, 15–39.
- Bousfield, G.R., Butnev, V.Y., Butnev, V.Y., Nguyen, V.T., Gray, C.M., Dias, J.A., MacColl, R., Eisele, L., Harvey, D.J., 2004. Differential Effects of a Asparagine⁵⁶ oligosaccharide structure on equine Lutropin and Follitropin hybrid conformation and receptor-binding activity. *Biochemistry* 43, 10817–10833.
- Bousfield, G.R., Butnev, V.Y., Walton, W.J., Nguyen, V.T., Singh, V., Hueneidi, J., Kolli, K., Harvey, D.J., Rance, N., 2007. All or none N-glycosylation in primate follicle-stimulating hormone β subunits. *Mol. Cell. Endocrinol.* 260–262, 40–48.
- Bousfield, G.R., Butnev, V.Y., Bidart, J.M., Dalpathado, D., Irungu, J., Desaire, H., 2008. Chromatofocusing fails to separate hFSH isoforms on the basis of glycan structure. *Biochemistry* 47, 1708–1720.
- Butnev, V.Y., Gotschall, R.R., Butnev, V.Y., Baker, V.L., Moore, W.T., Bousfield, G.R., 1998. Hormone-specific inhibitory influence of α -subunit Asn⁵⁶ oligosaccharide on *in vitro* subunit association and FSH receptor binding of equine gonadotropins. *Biol. Reprod.* 58, 458–469.
- Calvo, F.O., Keutmann, H.T., Bergert, E.R., Ryan, R.J., 1986. Deglycosylated human follitropin: characterization and effects on adenosine cyclic 3',5'-phosphate production in porcine granulosa cells. *Biochemistry* 25, 3938–3943.
- Dalpathado, D.S., Irungu, J.A., Go, E.P., Butnev, V.Y., Norton, K., Bousfield, G.R., Desaire, H., 2006. Comparative glycomics of the glycoprotein hormone follicle-stimulating hormone (FSH): glycopeptide analysis of isolates from two mammalian species. *Biochemistry* 45, 8665–8673.
- Fan, Q.R., Hendrickson, W.A., 2005. Structure of human follicle-stimulating hormone in complex with its receptor. *Nature* 433, 269–277.
- Flack, M.R., Froehlich, J., Bennet, A.P., Anasti, J., Nisula, B.C., 1994. Site-directed mutagenesis defines the individual roles of the glycosylation sites on follicle-stimulating hormone. *J. Biol. Chem.* 269, 14015–14020.
- Fox, K.M., Dias, J.A., Van Roey, P., 2001. Three-dimensional structure of human follicle-stimulating hormone. *Mol. Endocrinol.* 15, 378–389.
- Green, E.D., Baenziger, J.U., 1988. Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin II. Distributions of sulfated and sialylated oligosaccharides on bovine, ovine, and human pituitary glycoprotein hormones. *J. Biol. Chem.* 263, 36–44.
- Guan, R., Wu, X., Feng, X., Zhang, M., Hébert, T.E., Segaloff, D.L., 2010. Structural determinants underlying constitutive dimerization of unoccupied human follitropin receptors. *Cell Signal.* 22, 247–256.
- Harvey, D.J., Royle, L., Radcliffe, C.M., Rudd, P.M., Dwek, R.A., 2008. Structural and quantitative analysis of N-linked glycans by matrix-assisted laser desorption ionization and negative ion nanospray mass spectrometry. *Anal. Biochem.* 376, 44–60.
- Jiang, X., Liu, H., Chen, X., Chen, P.H., Fischer, D., Sriraman, V., Yu, H.N., Arkinstall, S., He, X., 2012. Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor. *Proc. Natl. Acad. Sci. USA* 109, 12491–12496.
- Jiang, X., Dias, J.A., He, X., 2013. Structural biology of glycoprotein hormones and their receptors: insights to signaling. *Mol. Cell. Endocrinol.* ePUB, S0303-7207.
- Liu, W.-K., Yang, K.-P., Nakagawa, Y., Ward, D.N., 1974. The role of the amino group in subunit association and receptor site interaction for ovine luteinizing hormone as studied by acylation. *J. Biol. Chem.* 249, 5544–5550.
- Liu, W.K., Young, J.D., Ward, D.N., 1984. Deglycosylated ovine lutropin: preparation and characterization by *in vitro* binding and steroidogenesis. *Mol. Cell. Endocrinol.* 37, 29–39.
- Mazurkiewicz, J.E., Thomas, R.M., Nachamen, C.A., Muda, M., Palmer, S., Dias, J.A., 2006. FSH receptor is synthesized as a dimer and proteolytically processed at the cell surface. *Faseb Journal.* 20, A115–A115.
- Padmanabhan, V., McFadden, K., Mauger, D.T., Karsch, F.J., Midgley, A.R.J., 1997. Neuroendocrine control of follicle-stimulating hormone (FSH) secretion. I. Direct evidence for separate episodic and basal components of FSH secretion. *Endocrinology* 138, 424–432.
- Parsons, T.F., Bloomfield, G.A., Pierce, J.C., 1983. Purification of an alternate form of the α subunit of the glycoprotein hormones from bovine pituitaries and identification of its O-linked oligosaccharide. *J. Biol. Chem.* 258, 240–244.
- Plant, T.M., Nakai, Y., Berchetz, P., Keogh, E., Knobil, E., 1978. The sites of action of estradiol and phentolamine in the inhibition of the pulsatile, circroral discharges of LH in the rhesus monkey (*Macaca mulatta*). *Endocrinology* 102, 1015–1018.
- Reame, N., Sauder, S.E., Kelch, R.P., Marshall, J.C., 1984. Pulsatile gonadotropin secretion during the human menstrual cycle: evidence for altered frequency of gonadotropin-releasing hormone secretion. *J. Clin. Endocrinol. Metab.* 59, 328–337.
- Renwick, A.G.C., Mizuochi, T., Kochibe, N., Kobata, A., 1987. The asparagine-linked sugar chains of human follicle-stimulating hormone. *J. Biochem.* 101, 1209–1221.
- Stanton, P.G., Hearn, M.T., 1987. The iodination sites of bovine thyrotropin. *J. Biol. Chem.* 262, 1623–1632.
- Timossi, C., Barrios-de-Tomasi, J., Gonzalez-Suarez, R., Arranz, M.C., Padmanabhan, V., Conn, P.M., Ulloa-Aguirre, A., 2000. Differential effects of the charge variants of human follicle-stimulating hormone. *J. Endocrinol.* 165, 193–205.
- Ulloa-Aguirre, A., Chappel, S.C., 1982. Multiple species of follicle-stimulating hormone exist within the anterior pituitary gland of male golden hamsters. *J. Endocrinol.* 95, 257–266.
- Ulloa-Aguirre, A., Cravioto, A., Damian-Matsumura, P., Jimenez, M., Zambrano, E., Diaz-Sanchez, V., 1992a. Biological characterization of the naturally occurring analogues of intrapituitary human follicle-stimulating hormone. *Hum. Reprod.* 7, 23–30.
- Ulloa-Aguirre, A., Damian-Matsumura, P., Jimenez, M., Zambrano, E., Diaz-Sanchez, V., 1992b. Biological characterization of the isoforms of urinary human follicle-stimulating hormone contained in a purified commercial preparation. *Hum. Reprod.* 7, 1371–1378.
- Urizar, E., Montanelli, L., Loy, T., Bonomi, M., Swillens, S., Gales, C., Bouvier, M., Smits, G., Vassart, G., Costagliola, S., 2005. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. *EMBO J.* 24, 1954–1964.
- Walton, W.J., Nguyen, V.T., Butnev, V.Y., Singh, V., Moore, W.T., Bousfield, G.R., 2001. Characterization of human follicle-stimulating hormone isoforms reveals a non-glycosylated β -subunit in addition to the conventional glycosylated β -subunit. *J. Clin. Endocrinol. Metab.* 86, 3675–3685.
- Ward, D.N., Glenn, S.D., Nahm, H.S., Wen, T., 1986. Characterization of cleavage products in selected human lutropin preparations. *Int. J. Peptide Prot. Res.* 27, 70–78.
- Weisshaar, G., Hiyama, J., Renwick, A.G.C., 1991. Site-specific N-glycosylation of human chorionic gonadotropin – structural analysis of glycopeptides by one- and two-dimensional ¹H NMR spectroscopy. *Glycobiology* 1, 393–404.
- West, C.R., Carlson, N.E., Lee, J.S., McNeilly, A.S., Sharma, T.P., Ye, W., Padmanabhan, V., 2002. Acidic mix of FSH isoforms are better facilitators of ovarian follicular maturation and E2 production than the less acidic. *Endocrinology* 143, 107–116.
- Wide, L., 1982. Male and female forms of human follicle-stimulating hormone in serum. *J. Clin. Endocrinol. Metab.* 55, 682–688.
- Wide, L., 1985. Median charge and charge heterogeneity of human pituitary FSH, LH and TSH. II. Relationship to sex and age. *Acta Endocrinol. (Copenh.)* 109, 190–197.
- Wide, L., 1987. Evidence for diverse structural variations of the forms of human FSH within and between pituitaries. *Acta Endocrinol.* 115, 7–15.
- Wide, L., Bakos, O., 1993. More basic forms of both human follicle-stimulating hormone and luteinizing hormone in serum at midcycle compared with the follicular or luteal phase. *J. Clin. Endocrinol. Metab.* 76, 885–889.
- Wide, L., Erickson, K., 2013. Dynamic changes in glycosylation and glycan composition of serum FSH and LH during natural ovarian stimulation. *Upsala J. Med. Sci.* 118, 153–164.
- Zambrano, E., Olivares, A., Mendez, J.P., Guerrero, L., Diaz-Cueto, L., Veldhuis, J.D., Ulloa-Aguirre, A., 1995. Dynamics of basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle. *J. Clin. Endocrinol. Metab.* 80, 1647–1656.